Shopping Cart

Remove All

Your shopping cart is currently empty

Tegoprazan

Select Batch

Purity:98.22%

Resource Download

COA HPLC HNMR

Tegoprazan

Catalog No. T17030Cas No. 942195-55-3

Tegoprazan is a potassium-competitive acid blocker and is a potent, oral active, and highly selective inhibitor of gastric H+/K+-ATPase. That could control gastric acid secretion and motility (IC50: ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro).

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Pack Size	Price	Availability
1 mg	$65	In Stock
5 mg	$159	In Stock
10 mg	$255	In Stock
25 mg	$513	In Stock
50 mg	$813	In Stock
100 mg	$1,230	In Stock
200 mg	$1,680	In Stock
1 mL x 10 mM (in DMSO)	$176	In Stock

Bulk & Custom

Add to Cart

Questions

Related Compound Libraries of "Tegoprazan"

Product Introduction

Bioactivity

Description	Tegoprazan is a potassium-competitive acid blocker and is a potent, oral active, and highly selective inhibitor of gastric H+/K+-ATPase. That could control gastric acid secretion and motility (IC50: ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro).
In vitro	Tegoprazan inhibits gastric H+/K+-ATPase in a potassium-competitive and reversible manner and it also inhibits porcine, canine, and human H+/K+-ATPase activity. Tegoprazan (3 μM) inhibits 86% of H+/K+-ATPase activity, whereas the inhibition is decreased to 34% after the dilution of Tegoprazan concentration to 0.15 μM [1].
In vivo	Tegoprazan (1.0-3.0 mg/kg, p.o.) reverses the pentagastrin-induced acidified gastric pH to the neutral range. Tegoprazan (1.0 mg/kg, p.o.) effectively and fully inhibits histamine-induced gastric acid secretion in dogs. Tegoprazan (3 mg/kg, p.o.) immediately evokes a gastric phase III contraction of the migrating motor complex in pentagastrin-treated dogs [1].

Chemical Properties

Molecular Weight	387.38
Formula	C20H19F2N3O3
Cas No.	942195-55-3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Solubility Information

DMSO: 22.5 mg/mL (58.08 mM)

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.5814 mL	12.9072 mL	25.8144 mL	129.0722 mL
5 mM	0.5163 mL	2.5814 mL	5.1629 mL	25.8144 mL
10 mM	0.2581 mL	1.2907 mL	2.5814 mL	12.9072 mL
20 mM	0.1291 mL	0.6454 mL	1.2907 mL	6.4536 mL
50 mM	0.0516 mL	0.2581 mL	0.5163 mL	2.5814 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:

For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments

A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent

DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。

Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO TargetMol | reagent

(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.

Preparation method for in vivo formula: Take 50 μL DMSO TargetMol | reagent

main solution, add 300 μLPEG300 TargetMol | reagent

mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O TargetMol | reagent

mix well and clarify

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc